Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort
Nonalcoholic fatty liver disease (NAFLD) has become the most common form of chronic liver disease in the USA. Interestingly, most patients with NAFLD are unaware of having any liver disease (LD). We aimed to assess the awareness of suspected NAFLD and factors associated with being aware of LD.
Adult subjects with suspected NAFLD (BMI > 25) with elevated ALT in the absence of secondary causes of LD who participated in the continuous national health and nutrition examination survey (NHANES) during 2001–2016 were identified and analyzed. Trends of NAFLD awareness were then assessed in periods of 4 years each. Multivariable logistic regression analysis was performed to assess factors associated with LD awareness.
A total of 7033 subjects were included in the final analysis (1731, 1757, 1711, and 1834 subjects for the periods of 2001–2004, 2005–2008, 2009–2012, and 2013–2016, respectively). Over the study duration, an increase in BMI, waist circumference, diabetes, and HbA1c; and a decrease in the number of smokers, platelets count, bilirubin, total cholesterol, and LDL level were noticed (p < 0.001). Awareness of having LD across study periods has increased over time from 1.5% in the 2001–2004 periods to 3.1% in the 2013–2016 periods. Multivariable logistic regression analysis showed that older age, ethnicity (non-black), having fewer drinks/week, metabolic syndrome, higher ALT, ALP, and GGT were associated with being aware of having LD.
Awareness of having LD among subjects with suspected NAFLD has increased over the last two decades, but more than 95% of these patients are still unaware of having LD. Educational programs to increase awareness of LD and risk factors for NAFLD should be implemented on a large scale.
Clinical Trial Registration Number
Not required, as we used de-identified NHANES data.
KeywordsNonalcoholic fatty liver disease (NAFLD) Noninvasive scores Awareness Liver disease
AST to platelet ration index
Body mass index
Centers for disease control and prevention
End-stage liver disease
Hepatic steatosis index
International diabetes federation
“Medical conditions” questionnaire
National health and nutrition examination survey
Nonalcoholic fatty liver disease
NAFLD fibrosis score
National center for health statistics
Upper limit of normal
AS, ASD, MG, and NA helped in study concept and design; AS contributed to acquisition of data; all authors helped in analysis and interpretation of data, drafting of the manuscript and critical revision of the manuscript for important intellectual content, and administrative, technical, or material support; RL, AS, and NA contributed to statistical analysis; ASD, SS, AK, AK, MN, WC, AM, and NA contributed to study supervision.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 13.Federation ID. The IDF Consensus Worldwide Definition of the Metabolic Syndrome 2011. https://www.pitt.edu/~super1/Metabolic/IDF1.pdf. Accessed 30 Jan 2019.
- 15.Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey: analytic guidelines, 1999–2010. Vital Health Stat. 2013;2:1–24.Google Scholar
- 21.Coogan PE, Wise LA, Cozier YC, Palmer JR, Rosenberg L. Lifecourse educational status in relation to weight gain in African American women. Ethn Dis. 2012;22:198–206.Google Scholar
- 23.Grattagliano I, D’Ambrosio G, Palmieri VO, et al. Improving nonalcoholic fatty liver disease management by general practitioners: a critical evaluation and impact of an educational training program. J Gastrointestin Liver Dis. 2008;17:389–394.Google Scholar
- 25.Singh Sp MB, Misra D, Pati GK, et al. Awareness and opinion of nonalcoholic fatty liver disease (NAFLD) patients about obesity and its consequences. J Hepatol. 2014;60:S352.Google Scholar
- 30.Goldberg RB, Temprosa M, Haffner S, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009;32:726–732.CrossRefGoogle Scholar